The Cooper Companies, Inc. (NASDAQ:COO) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of The Cooper Companies, Inc. (NASDAQ:COO) have earned a consensus recommendation of “Moderate Buy” from the twelve ratings firms that are covering the stock, Marketbeat reports. Three equities research analysts have rated the stock with a hold rating and nine have issued a buy rating on the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $117.00.

A number of equities research analysts recently issued reports on COO shares. Stifel Nicolaus reaffirmed a “buy” rating and set a $115.00 price target (up previously from $110.00) on shares of Cooper Companies in a research note on Thursday, August 29th. Needham & Company LLC reaffirmed a “hold” rating on shares of Cooper Companies in a report on Friday, December 6th. Piper Sandler boosted their price objective on Cooper Companies from $115.00 to $120.00 and gave the stock an “overweight” rating in a research note on Thursday, August 29th. Robert W. Baird raised their price objective on Cooper Companies from $118.00 to $125.00 and gave the company an “outperform” rating in a research note on Thursday, August 29th. Finally, StockNews.com downgraded Cooper Companies from a “buy” rating to a “hold” rating in a research report on Wednesday, December 11th.

Cooper Companies Stock Up 1.6 %

COO opened at $93.44 on Friday. The company has a market capitalization of $18.65 billion, a PE ratio of 47.92, a price-to-earnings-growth ratio of 2.52 and a beta of 0.97. The firm has a 50-day simple moving average of $102.20 and a two-hundred day simple moving average of $98.89. The company has a quick ratio of 1.12, a current ratio of 1.91 and a debt-to-equity ratio of 0.32. Cooper Companies has a 52 week low of $84.76 and a 52 week high of $112.38.

Cooper Companies (NASDAQ:COO) last announced its quarterly earnings results on Thursday, December 5th. The medical device company reported $1.04 EPS for the quarter, beating analysts’ consensus estimates of $1.00 by $0.04. Cooper Companies had a return on equity of 9.38% and a net margin of 10.07%. The company had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1.03 billion. During the same period in the prior year, the company earned $0.87 earnings per share. The firm’s revenue was up 9.8% on a year-over-year basis. Analysts forecast that Cooper Companies will post 3.98 earnings per share for the current fiscal year.

Institutional Trading of Cooper Companies

A number of large investors have recently made changes to their positions in the stock. Innealta Capital LLC bought a new stake in Cooper Companies during the 2nd quarter valued at about $25,000. Ashton Thomas Securities LLC purchased a new position in shares of Cooper Companies during the third quarter worth approximately $25,000. Crewe Advisors LLC raised its stake in shares of Cooper Companies by 286.4% during the second quarter. Crewe Advisors LLC now owns 340 shares of the medical device company’s stock valued at $30,000 after acquiring an additional 252 shares in the last quarter. Tortoise Investment Management LLC boosted its holdings in shares of Cooper Companies by 75.4% in the second quarter. Tortoise Investment Management LLC now owns 393 shares of the medical device company’s stock valued at $34,000 after purchasing an additional 169 shares during the period. Finally, Covestor Ltd grew its stake in Cooper Companies by 144.9% in the third quarter. Covestor Ltd now owns 338 shares of the medical device company’s stock worth $37,000 after purchasing an additional 200 shares in the last quarter. 24.39% of the stock is owned by hedge funds and other institutional investors.

About Cooper Companies

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.